
Page#1
 
 
NOVAVAX, INC.
 
CONSOLIDATED BALANCE SHEETS
 
  December 31, 
  2017 2016 
(in thousands, except share and per
  share information) 
ASSETS
Current assets: 
Cash and cash equivalents  $ 106,307  $ 144,353 
Marketable securities 50,996 91,126 
Restricted cash 28,234 30,314 
Prepaid expenses and other current assets 17,774 22,037 
Total current assets 203,311 287,830 
Restricted cash 890 4,590 
Property and equipment, net 35,987 40,184 
Intangible assets, net 7,873 9,225 
Goodwill 53,563 51,673 
Other non-current assets 869 799 
 
Total assets $ 302,493 $ 394,301
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities: 
Accounts payable  $ 5,613  $ 5,685 
Accrued expenses 29,610 24,508 
Accrued interest 5,078 5,078 
Deferred revenue 25,625 30,079 
Other current liabilities 7,749 1,056 
Total current liabilities 73,675 66,406 
Deferred revenue 2,500 2,500 
Convertible notes payable 317,763 316,339 
Other non-current liabilities 10,287 14,602 
Total liabilities 404,225 399,847 
 
Commitments and contingencies — — 
Stockholders’ deficit: 
Preferred stock, $0.01 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31,
2017 and 2016 — — 
Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2017 and 2016; and 323,684,820
shares issued and 323,229,390 shares outstanding at December 31, 2017 and 271,701,397 shares issued and
271,245,967 shares outstanding at December 31, 2016 3,237 2,717 
Additional paid-in capital 1,020,457 935,997 
Accumulated deficit (1,114,359) (929,996)
Treasury stock, 455,430 shares, cost basis at both December 31, 2017 and 2016 (2,450) (2,450)
Accumulated other comprehensive loss (8,617) (11,814)
Total stockholders’ deficit (101,732) (5,546)
 
Total liabilities and stockholders’ deficit $ 302,493 $ 394,301
 
 
The accompanying notes are an integral part of these financial statements.
 
 F-4 
Page#2
 
 
NOVAVAX, INC.
 
CONSOLIDATED STATEMENTS OF OPERATIONS
 
  Year Ended December 31, 
  2017 2016 2015 
  (in thousands, except per share information) 
 
Revenue: 
Government contract  $ —  $ 2,184  $ 33,344 
Grant and other 31,176 13,169 2,906 
Total revenue 31,176 15,353 36,250 
 
Expenses: 
Research and development 168,435 237,939 162,644 
General and administrative 34,451 46,527 30,842 
Total expenses 202,886 284,466 193,486 
Loss from operations (171,710) (269,113) (157,236)
Other income (expense): 
Investment income 1,946 2,143 660 
Interest expense (14,072) (12,965) (241)
Other income (expense) 67 (31) (120)
Net loss  )  )  )
$ (183,769 $ (279,966 $ (156,937
 
Basic and diluted net loss per share  )  )  )
$ (0.63 $ (1.03 $ (0.60
 
Basic and diluted weighted average number of common shares outstanding 
 292,669  270,802  262,248
 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
 
  Year Ended December 31, 
  2017 2016 2015 
  (in thousands) 
 
Net loss  $ (183,769)  $ (279,966)  $ (156,937)
Other comprehensive income (loss): 
Net unrealized (losses) gains on marketable securities available-for-sale (50) 54 42 
Foreign currency translation adjustment 3,247 (2,744) (2,561)
Other comprehensive income (loss) 3,197 (2,690) (2,519)
Comprehensive loss  )  )  )
$ (180,572 $ (282,656 $ (159,456
 
The accompanying notes are an integral part of these financial statements.
 
 F-5 
Page#3
 
 
NOVAVAX, INC.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
  Year Ended December 31, 
  2017 2016 2015 
  (in thousands) 
Operating Activities: 
Net loss  $ (183,769)  $ (279,966)  $ (156,937)
Reconciliation of net loss to net cash used in operating activities: 
Depreciation and amortization 9,817 8,505 5,983 
Loss on disposal of property and equipment 269 374 681 
Amortization of debt issuance costs 1,424 1,305 ― 
Lease incentives received 1,933 1,963 2,792 
Non-cash stock-based compensation 19,809 19,160 13,431 
Other 2,715 663 1,460 
Changes in operating assets and liabilities: 
Restricted cash 5,780 3,301 (36,204)
Prepaid expenses and other assets 2,590 (1,119) (1,790)
Accounts payable and accrued expenses 5,192 (4,808) 9,075 
Deferred revenue (4,456) (6,057) 36,140 
Other liabilities ― 1,212 (721)
Net cash used in operating activities (138,696) (255,467) (126,090)
 
Investing Activities: 
Capital expenditures (4,189) (18,202) (18,268)
Purchases of marketable securities (218,045) (356,556) (228,521)
Proceeds from maturities of marketable securities 258,202 402,775 225,519 
Net cash provided by (used in) investing activities 35,968 28,017 (21,270)
 
Financing Activities: 
Principal payments of capital leases (37) (71) (67)
Principal payments of notes payable ― (395) (600)
Changes in restricted cash ― (819) (126)
Proceeds from issuance of convertible notes ― 325,000 ― 
Payments of costs related to issuance of convertible notes ― (9,966) ― 
Payments for capped call transactions and costs ― (38,521) ― 
Net proceeds from sales of common stock 63,425 ― 204,275 
Proceeds from the exercise of stock options and employee stock purchases 1,152 3,802 4,801 
Net cash provided by financing activities 64,540 279,030 208,283 
Effect of exchange rate on cash and cash equivalents 142 (335) (150)
Net (decrease) increase in cash and cash equivalents (38,046) 51,245 60,773 
Cash and cash equivalents at beginning of year 144,353 93,108 32,335 
Cash and cash equivalents at end of year 
$ 106,307 $ 144,353 $ 93,108
 
Supplemental disclosure of non-cash activities: 
Capital expenditures included in accounts payable and accrued expenses 
$ 15 $ 697 $ 2,797
 
Supplemental disclosure of cash flow information: 
Cash interest payments 
$ 12,188 $ 6,189 $ 96
 
The accompanying notes are an integral part of these financial statements.
 
 F-7 